Safety assessments
All baseline and safety data were analyzed using the safety population. The safety population included all enrolled subjects who received at least one dose of study medication and had at least one postdose safety assessment.AEs were assessed and recorded from the first day of SDX/d-MPH administration through the end of the study through either follow-up or early termination. Both rollover and new subjects completed a follow-up visit ∼3 days after the last dose of SDX/d-MPH. A complete medical history was obtained at the screening visit. Physical examinations, clinical laboratory assessments, and ECGs were performed at screening, after ∼6 months of treatment, and at the end of the treatment phase. Vital signs (sitting blood pressure, pulse rate, respiratory rate, and oral temperature) were assessed at each study visit.For safety assessments, descriptive statistics were reported for continuous and categorical data. 